Can a glucose monitor boost diabetes remission? new trial aims to find out
NCT ID NCT07157384
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will test whether using a continuous glucose monitor (isCGM) helps more people with type 2 diabetes achieve remission compared to standard finger-stick testing. Both groups will follow a low-calorie meal replacement plan and receive diabetes education. The trial aims to enroll 176 adults and will track remission rates after 18-30 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- intermittently scanned continuous glucose monitor (isCGM) device
- What this could lead to
- If it works, this could show that using a continuous glucose monitor helps more people with type 2 diabetes achieve remission through diet and education.
- What could go wrong
- This is a relatively small, early-stage trial (176 people) that has not yet started. The remission may not last long-term, and the diet plan is very low-calorie, which can be hard to stick with.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 176 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-75 years old * T2D treated with ≤ 3 non-insulin antihyperglycemic agents * A clinical diagnosis of T2D for \> 6 months and ≤ 6 years ago * HbA1c 6.0-9.0% on 2 or 3 antihyperglycemic agents, HbA1c 6.5-9.0% on 1 antihyperglycemic agent, or HbA1c 7.0-9.0% on 0 antihyperglycemic agents * BMI 27-44.9 kg/m2 * Not currently using a real-time CGM or isCGM * Willing to adhere to LCMR and initiate isCGM or CBG monitoring, and capable to do so as judged by investigator Exclusion Criteria: * Current or prior use of insulin (except for prior management of gestational diabetes mellitus) * Are pregnant or breastfeeding, or planning to become pregnant in the next 2 years * Severe or progressive retinopathy * Have a history of cardiovascular disease: coronary artery disease (CAD): prior myocardial infarction, previous unstable angina, documented CAD on angiography with stenosis \>50%, imaging evidence of myocardial ischemia, coronary revascularization), peripheral arterial disease (lower extremity stenosis exceeding 50%, previous limb angioplasty, stenting or bypass surgery; or previous limb or foot amputation due to circulatory insufficiency or ankle brachial index of \< 0.9 in at least one limb.), cerebrovascular disease (history of ischemic or hemorrhagic stroke or \> 50% carotid stenosis), or heart failure * Chronic kidney disease with estimated glomerular filtration rate (eGFR) \< 60 ml/min/1.73 m2 or eGFR 60-90 ml/min/1.73 m2 with urine albumin to creatinine ratio (uACR) \> 20 mg/mmol (any previously resolved macroalbuminuria will be considered as a reason for ineligibility, at the investigator's discretion) * Active binge eating disorder or other eating disorder * Uncontrolled mental health disorder * Current use of atypical antipsychotic or corticosteroid * Use of other implanted medical devices, such as pacemakers * Participant whose circumstance is deemed by investigator to be unadvisable, unsafe, or unlikely to be capable of adhering to LCMR and/or isCGM/CBG monitoring during the study period
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
LMC Bayview
Toronto, Ontario, M4G 3E8, Canada
-
LMC Brampton
Brampton, Ontario, Canada
-
LMC Etobicoke
Etobicoke, Ontario, Canada
-
LMC Oakville
Oakville, Ontario, Canada
-
LMC Ottawa
Ottawa, Ontario, Canada
-
LMC Vaughan
Vaughan, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness and yoga rewire diabetes habits?
- Can a vegan diet delivered online help people with type 2 diabetes?
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Gut microbes in pregnancy and infancy: a window into lifelong health?
- A blood test at 50 could flag your risk of five diseases. can an app stop them?
- Chatbot coach takes aim at diabetes risk after pregnancy